Clinical Trial: Endpoint Validation Study (0524A-015)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM)

Brief Summary: To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: To determine the most effective daily dose and measurements to assess acute and chronic (long-lasting) Niacin Induce Flushing (NIF). [ Time Frame: 8 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: To assess the the time points of Niacin Induce Flushing (NIF) across the 8-week treatment period. [ Time Frame: 8 weeks ]

Original Secondary Outcome: Same as current

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: September 19, 2007
Date Started: August 2004
Date Completion:
Last Updated: February 16, 2017
Last Verified: February 2017